Exousia Bio, Inc.: cash including restricted cash
Cash including restricted cash for Exousia Bio, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Exousia Bio, Inc. financial histories
What this measure means
Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.
Exact concept: us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-01-31 to 2025-05-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-05-31 | 0 | USD | 2025-10-17 | 10-K · 0001683168-25-007621 |
| At date | 2024-05-31 | 1,028 | USD | 2025-10-17 | 10-K · 0001683168-25-007621 |
| At date | 2023-05-31 | 7,855 | USD | 2025-10-17 | 10-K · 0001683168-25-007621 |
| At date | 2022-05-31 | 10,107 | USD | 2024-08-30 | 10-K · 0001683168-24-006126 |
| At date | 2022-01-31 | 0 | USD | 2023-09-01 | 10-K · 0001683168-23-006240 |
Related financial histories
- Exousia Bio, Inc.: total assets
- Exousia Bio, Inc.: total liabilities
- Exousia Bio, Inc.: stockholders equity
- Exousia Bio, Inc.: net income or loss
- Exousia Bio, Inc.: operating cash flow
- Exousia Bio, Inc.: revenue
- Exousia Bio, Inc.: financing cash flow
- Exousia Bio, Inc.: retained earnings or deficit
- Exousia Bio, Inc.: basic weighted-average shares
- Exousia Bio, Inc.: diluted weighted-average shares
- Exousia Bio, Inc.: net property, plant and equipment
- Exousia Bio, Inc.: current assets
- Exousia Bio, Inc.: current liabilities
- Exousia Bio, Inc.: net current accounts receivable
- Exousia Bio, Inc.: operating expenses
- Exousia Bio, Inc.: gross profit
- Exousia Bio, Inc.: cost of revenue
- Exousia Bio, Inc.: common shares outstanding
- Exousia Bio, Inc.: additional paid-in capital
- Exousia Bio, Inc.: net intangible assets excluding goodwill
- Exousia Bio, Inc.: accrued current liabilities
- Exousia Bio, Inc.: pre-tax income or loss from continuing operations
- Exousia Bio, Inc.: general and administrative expense
- Exousia Bio, Inc.: depreciation expense
- Exousia Bio, Inc.: other nonoperating income or expense
- Exousia Bio, Inc.: proceeds from issuing common stock
- Exousia Bio, Inc.: change in accounts receivable
Inspect the source
- Entity
- Exousia Bio, Inc. / CIK 0001939937
- Captured
- 2026-09-21T17:37:11.061Z
- SEC response SHA-256
f2baaf88a0d63e649210121b2d933b643581fa6f32939fbe1708e0e1758d9550
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001939937.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))